Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
| Author | Mihajlo Jakovljevic | en |
| Author | Zeljko Mijailovic | en |
| Author | Biljana Popovska Jovicic | en |
| Author | Predrag Canovic | en |
| Author | Olgica Gajovic | en |
| Author | Mirjana Jovanovic | en |
| Author | Dejan Petrovic | en |
| Author | Olivera Milovanovic | en |
| Author | Natasa Djordjevic | en |
| Issued Date | 2013-06-01 | en |
| Abstract | Background: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. Objectives: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). Patients and Materials: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. Results: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). Conclusion: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected. | en |
| DOI | https://doi.org/10.5812/hepatmon.6750 | en |
| URI | https://brieflands.com/journals/hepatmon/articles/15193 | en |
| Keyword | Cost-Benefit Analysis | en |
| Keyword | Interferons | en |
| Keyword | Ribavirin | en |
| Keyword | Hepatitis C | en |
| Keyword | Chronic | en |
| Publisher | Brieflands | en |
| Title | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 15193-pdf.pdf
- Size:
- 400.44 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF